Asthma
Adjunct
In severe asthma at 2024 steps 4–5, tiotropium is added to ICS+LABA as triple therapy. Reduces exacerbation frequency and improves lung function. Not used as asthma monotherapy.
Long-acting muscarinic antagonist (LAMA), inhaled
ATC code: R03BB04 (Tiotropium)
A long-acting competitive antagonist of M1, M2, and M3 muscarinic receptors in airway smooth muscle. Selectively maintains M3 binding for over 24 hours, sustaining bronchodilation. Reduces vagal tone, dilates bronchi, and decreases mucus hypersecretion. Onset within 30 minutes; peak 1–3 hours.
Adjunct
In severe asthma at 2024 steps 4–5, tiotropium is added to ICS+LABA as triple therapy. Reduces exacerbation frequency and improves lung function. Not used as asthma monotherapy.
First line
First-line in stable COPD groups B, C, and D under 2024. Cuts exacerbation frequency by 14% and improves FEV1, exercise capacity, and quality of life (UPLIFT, POET-COPD). Used as LAMA monotherapy or with a LABA (tiotropium + olodaterol). In frequent-exacerbator phenotypes, add ICS.
The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.
Not recommended
Tiotropium is a long-acting inhaled antimuscarinic (LAMA). It is prescribed for COPD and severe asthma as add-on therapy ( 2024, 2024). Tiotropium is used in inhaler form for enhanced breathing and exercise-related breathing difficulty outside a COPD or severe asthma indication. No clinical studies of prophylactic use in this setting exist. The drug causes dry mouth, urinary retention (especially in men with benign prostatic hyperplasia), and elevated intraocular pressure (especially in angle-closure glaucoma). If tiotropium was prescribed outside confirmed COPD or severe asthma, consider seeking a second opinion.
Opens the checker prefilled with this drug. Pick the second one from your regimen.
Direct links to regulator labels. Open in a new tab.
Limited data. Use in pregnancy is acceptable when potential maternal benefit justifies potential fetal risk.
No data on milk excretion. Use during lactation only when indicated.
Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.
Tiotropium is evaluated for the following indications with varying evidence strength: Asthma (evidence tier A), Chronic obstructive pulmonary disease (evidence tier A), Immune support and respiratory infection care (evidence tier F). See the full indication matrix with dosing and citations above on this page.
Common side effects of Tiotropium (≥ 1 in 100): Dry mouth (5–10%), Cough, Pharyngitis, Constipation, Headache. See the Safety section for uncommon and serious reactions.
FDA category C. Limited data. Use in pregnancy is acceptable when potential maternal benefit justifies potential fetal risk.
No data on milk excretion. Use during lactation only when indicated.
Tiotropium is contraindicated in: Hypersensitivity to tiotropium, atropine, or derivatives; Age under 6 (Respimat) or under 18 (HandiHaler). Full list in the Safety section.